Skip to main content

Advertisement

Table 1 Summary of clinical studies addressing the outcome of patients with steroid-refractory GvHD treated with MSCs

From: Mesenchymal stromal cells for treatment of steroid-refractory GvHD: a review of the literature and two pediatric cases

     outcome (total) outcome (%)  
study # of patients (children/adults) mean age (years) sex (m/f) CR PR NR CR PR NR reference
1 19 adults 27.5 14/5 4 10 5 21.1 52.6 26.3 Weng JY 2010
2 7 children 14 ns 3 1 3 42.9 14.3 42.9 Muller I 2008
3 55 (25 children, 30 adults) 22 34/21 30 9 16 54.5 16.4 29.1 Le Blanc K 2008
4 12 adults ns ns 3 6 3 25.0 50.0 25.0 Zhang LS 2009
5 13 adults 58 7/6 1 1 11 7.7 7.7 84.6 von Bonin M 2009
6 2 children, 6 adults 43.25 7/1 6 0 2 75.0 0.0 25.0 Ringdén O 2006
7 31 adults 52 21/10 24 5 2 77.4 16.1 6.5 Kebriaei P 2009
8 6 adults 40 2/4 5 0 1 83.3 0.0 16.7 Fang B 2007
9 12 children 7 10/2 7 5 0 58.0 42.0 0.0 Prasad VK 2010
10 2 adults 32 1/1 0 2 0 0.0 100 0.0 Lim JH 2010
11 3 adults 48 1/2 0 1 2 0 33.3 66.7 Arima N 2010
12 11 children 9 8/3 3 5 3 27.3 45.4 27.3 Lucchini G 2010
13 2 children 13.5 1/1 2 0 0 100 0 0 Fang B 2007
14 2 children 11.5 1/1 2 0 0 100 0 0 present study
  mean age range 27.0 0.5-67 65.2/34.8%        
  1. Apart from the present study only those studies were included that reported on at least 2 individuals and that were available at MEDLINE® (NCBI) until June 2011. CR = complete response; PR = partial response; NR = no response; ns = not specified. Children was defined as age < 18 years.